Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Clinical Research Associates LLC currently has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This matter is assigned to KASSA, TIGABU, who is the busiest examiner for the portfolio with 1 pending office action. The portfolio's current activity is limited to 1 distinct examiner and 1 distinct art unit. With 1 pending office action total, the company's current prosecution workload is highly centralized.
The involvement of only 1 distinct examiner, KASSA, TIGABU, means that the immediate patenting goals for this portfolio are tied to the outcome of a single case. This focus within 1 distinct art unit suggests that the company is pursuing a specific technical path within the biotechnology sector, requiring a targeted response to the examiner's findings. This streamlined environment can lead to more predictable prosecution timelines and a more cohesive patent strategy. Practitioners should note that this centralized approach allows for a more efficient use of resources when responding to USPTO communications. The successful resolution of this single pending matter will be a vital step in securing the company's intellectual property in the Biotechnology & Pharmaceuticals area. By focusing on the feedback from a single examiner, the company can ensure its patenting goals are met with precision and clarity.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KASSA, TIGABU | 1 | 36.7% | +27.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18331693 | ORALLY DISINTEGRATING BACLOFEN COMPOSITIONS AND METHODS OF MAKING SAME | KASSA, TIGABU | — |
| Art Unit | Apps |
|---|---|
| 1619 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18331693 | ORALLY DISINTEGRATING BACLOFEN COMPOSITIONS AND METHODS OF MAKING SAME | KASSA, TIGABU | 1619 | §103 | Non-Final OA | — | Pending | Jun 08, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialClinical Research Associates LLC has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Tigabu Kassa has the most, with 1 of Clinical Research Associates LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
